Cocrystal Pharma Announces Uplist to The Nasdaq Capital Market

- Company’s common stock to commence trading on Nasdaq on March 12, 2018 -

ATLANTA, GA and BOTHELL, WA, March 12, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses, today announced that its shares of common stock were approved for listing on The Nasdaq Capital Market.

The Company’s common stock will commence trading on The Nasdaq Capital Market today, March 12, 2018, and will continue to trade under the symbol “COCP.”

Gary Wilcox, Vice Chairman and Interim Chief Executive Officer of Cocrystal, commented, “Our uplisting to Nasdaq is a major corporate milestone for Cocrystal and will be integral in maximizing our opportunities and visibility to a broader base of investors, which we believe is key in unlocking shareholder value in both the near and long-term."

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HCV. Phase 1b studies in HCV infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 4 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 60% of the Company, including the Frost Group. OPKO Health, Inc., Brace Pharma Capital, LLC and Teva Pharmaceuticals Industries, Ltd. are corporate investors. For further information about Cocrystal, please visit www.cocrystalpharma.com

Forward-Looking Statements

This press release contains forward-looking statements including the commencement of a Phase 2a study and maximizing future opportunities. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include the availability of products manufactured by third parties, obtaining regulatory approval and the ability of the clinical research organization conducting the Phase 2a study to recruit subjects. Further information on our risk factors is contained in our filings with the SEC, including our Form 10-K for the year ended December 31, 2016. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
(908) 938-1475
jtc@jtcir.com

Primary Logo

Source: Cocrystal Pharma, Inc.